PharmaResearch (214450) Fundamentals 2026 — P/E 19.0x, Revenue Analysis | SniperIQ
PharmaResearch (214450) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩3.35T, trading at ₩322500.00 on the KOE. This SniperIQ fundamentals page covers PharmaResearch's valuation (P/E 19.0x, P/B 4.9x), profitability (net margin 31.2%), revenue (₩535.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PharmaResearch's market cap?
PharmaResearch (214450) has a market capitalization of approximately ₩3.35T, trading at ₩322500.00 on the KOE. Market cap moves with the live share price.
What is PharmaResearch's P/E ratio?
PharmaResearch's trailing twelve-month P/E ratio is 19.0x, with a price-to-book (P/B) of 4.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PharmaResearch?
PharmaResearch runs a net profit margin of 31.2%, a gross margin of 75.6%, and an operating margin of 39.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PharmaResearch generate?
PharmaResearch reported revenue of ₩535.7B for fiscal year 2025, with net income of ₩165.1B and earnings per share (EPS) of 15893. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PharmaResearch pay a dividend?
PharmaResearch offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PharmaResearch financially healthy?
PharmaResearch carries a debt-to-equity ratio of 0.31x and a current ratio of 5.69x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PharmaResearch a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PharmaResearch (214450) the key facts are: market cap ₩3.35T, P/E 19.0x, revenue ₩535.7B, 52-week range 255000-713000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PharmaResearch's full fundamentals live
Get PharmaResearch's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.